News coverage about Aerie Pharmaceuticals (NASDAQ:AERI) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.245911597922 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research raised Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 17th. ValuEngine upgraded Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Mizuho reaffirmed a “buy” rating and issued a $77.00 price target on shares of Aerie Pharmaceuticals in a research note on Wednesday, May 9th. Seaport Global Securities reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Monday, March 5th. Finally, BidaskClub lowered Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 11th. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Aerie Pharmaceuticals has a consensus rating of “Buy” and an average price target of $76.50.
Aerie Pharmaceuticals traded down $0.95, reaching $64.05, during midday trading on Tuesday, according to MarketBeat. 10,922 shares of the company’s stock traded hands, compared to its average volume of 543,407. Aerie Pharmaceuticals has a 52 week low of $47.05 and a 52 week high of $71.30. The company has a debt-to-equity ratio of 0.52, a current ratio of 13.57 and a quick ratio of 13.53. The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of -19.01 and a beta of 0.91.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Tuesday, May 8th. The company reported ($0.83) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.04. sell-side analysts expect that Aerie Pharmaceuticals will post -3.75 EPS for the current fiscal year.
In related news, insider Casey C. Kopczynski sold 2,708 shares of the business’s stock in a transaction dated Tuesday, May 29th. The shares were sold at an average price of $50.15, for a total transaction of $135,806.20. Following the transaction, the insider now owns 194,517 shares in the company, valued at $9,755,027.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vicente Anido, Jr. sold 150,000 shares of the stock in a transaction dated Friday, June 8th. The stock was sold at an average price of $62.28, for a total transaction of $9,342,000.00. Following the completion of the transaction, the chief executive officer now directly owns 176,320 shares of the company’s stock, valued at $10,981,209.60. The disclosure for this sale can be found here. Insiders sold 263,708 shares of company stock valued at $16,249,556 in the last ninety days. 10.53% of the stock is currently owned by insiders.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.